Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors
C. Guigoni(Centre National de la Recherche Scientifique), Erwan Bézard(Centre National de la Recherche Scientifique), U Mach(Goethe University Frankfurt), Pierre Sokoloff(Inserm), Q. Li(China Agricultural University), Bernard Bioulac(Centre National de la Recherche Scientifique), Gilberto Fisone(Karolinska Institutet), Vsevolod V. Gurevich(Vanderbilt University), Eugenia V. Gurevich(Vanderbilt University), Incarnation Aubert(Centre National de la Recherche Scientifique), Holger Stark(Goethe University Frankfurt), L. Leriche(Inserm), Katarina Håkansson(Karolinska Institutet), J.L. Benovic(Thomas Jefferson University), Christian E. Gross(Centre National de la Recherche Scientifique), Bertrand Bloch(Victor (Japan)), Sandrine Ferry(Inserm)
Cited by 134
Related Papers
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
|Pharmacological Reviews|2015|558
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
|The Lancet Neurology|2015|508
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
|Journal of Medicinal Chemistry|2018|476
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
|Progress in Neurobiology|2015|472
Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in L-DOPA-Induced Dyskinesia
|Journal of Neuroscience|2007|433